GAEU Consulting’s Client Qlucore secures €2.5M from EIC Accelerator Horizon Europe

GAEU Consulting’s Client Qlucore secures €2.5 Million from EIC Accelerator Horizon Europe.

Qlucore, a pioneer in cancer diagnostic software development, has received a €2.5 million grant from the EIC Accelerator Horizon Europe to spearhead the development and eventual introduction of CE-marked software solutions targeted for AML and bladder cancer diagnoses. The project is centred on addressing the critical need for better diagnostics in malignancies with complicated RNA-level changes. Qlucore’s research, which uses RNA-based technologies, promises to open up new dimensions in cancer diagnosis and therapy, ensuring that patients receive the most effective treatments tailored to their unique needs.

Carl-Johan Ivarsson, CEO of Qlucore AB comments: “We are clearly in the forefront of RNA- seg based modern clinical diagnostics and with the funding we will develop solutions both for acute myeloid leukemia (AML) and bladder cancer with the objective to advance personalized cancer treatment. We express our appreciation for the expert assistance and guidance provided by GAEU Consulting in the development of our application within the EIC Accelerator program. The team at GAEU possesses a high level of proficiency in navigating this process, offering crucial feedback, and demonstrating a high level of knowledge. Working with GAEU has been a very positive experience.”

Tomasz Wąsik, CEO GAEU Horizon Centre of Excellence, comments: “Being part of this groundbreaking initiative with Qlucore is not just a matter of pride for us at GAEU; it’s a testament to our commitment to fostering advancements in healthcare technology. This achievement is a clear indication of our team’s hard work and the innovative potential of Qlucore’s project. We’re all looking forward to seeing the impact of this work on enhancing personalized cancer treatment and diagnostics.”